A Five Year Randomized Controlled Trial to Assess the Efficacy and Antibody Responses to a Commercial and Autogenous Vaccine for the Prevention of Infectious Bovine Keratoconjunctivitis
A randomized control trial was performed over a five-year period to assess the efficacy and antibody response induced by autogenous and commercial vaccine formulations against infectious bovine keratoconjunctivitis (IBK). Calves were randomly assigned each year to one of three arms: an autogenous va...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/6/916 |
| _version_ | 1827656039435075584 |
|---|---|
| author | Matthew M. Hille Matthew L. Spangler Michael L. Clawson Kelly D. Heath Hiep L. X. Vu Rachel E. S. Rogers John Dustin Loy |
| author_facet | Matthew M. Hille Matthew L. Spangler Michael L. Clawson Kelly D. Heath Hiep L. X. Vu Rachel E. S. Rogers John Dustin Loy |
| author_sort | Matthew M. Hille |
| collection | DOAJ |
| description | A randomized control trial was performed over a five-year period to assess the efficacy and antibody response induced by autogenous and commercial vaccine formulations against infectious bovine keratoconjunctivitis (IBK). Calves were randomly assigned each year to one of three arms: an autogenous vaccine treatment that included <i>Moraxella bovis</i> (<i>M. bovis</i>), <i>Moraxella bovoculi</i>, and <i>Mycoplasma bovoculi</i> antigens, a commercial <i>M. bovis</i> vaccine treatment, or a sham vaccine treatment that consisted only of adjuvant. A total of 1198 calves were enrolled in the study. Calves were administered the respective vaccines approximately 21 days apart, just prior to turnout on summer pastures. Treatment effects were analyzed for IBK incidence, retreatment incidence, 205-day adjusted weaning weights, and antibody response to the type IV pilus protein (pili) of <i>M. bovis</i> as measured by a novel indirect enzyme-linked immunosorbent screening assay (ELISA). Calves vaccinated with the autogenous formulation experienced a decreased cumulative incidence of IBK over the entire study compared to those vaccinated with the commercial and sham formulations (24.5% vs. 30.06% vs. 30.3%, respectively, <i>p</i> = 0.25), and had less IBK cases that required retreatment compared to the commercial and sham formulations (21.4% vs. 27.9% vs. 34.3%, respectively, <i>p</i> = 0.15), but these differences were not significant. The autogenous formulation induced a significantly stronger antibody response than the commercial (<i>p</i> = 0.022) and sham formulations (<i>p</i> = 0.001), but antibody levels were not significantly correlated with IBK protection (<i>p</i> = 0.37). |
| first_indexed | 2024-03-09T22:17:01Z |
| format | Article |
| id | doaj.art-28f7ab7ae6b94016a94d056960f9ae3b |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T22:17:01Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-28f7ab7ae6b94016a94d056960f9ae3b2023-11-23T19:21:23ZengMDPI AGVaccines2076-393X2022-06-0110691610.3390/vaccines10060916A Five Year Randomized Controlled Trial to Assess the Efficacy and Antibody Responses to a Commercial and Autogenous Vaccine for the Prevention of Infectious Bovine KeratoconjunctivitisMatthew M. Hille0Matthew L. Spangler1Michael L. Clawson2Kelly D. Heath3Hiep L. X. Vu4Rachel E. S. Rogers5John Dustin Loy6School of Veterinary Medicine and Biomedical Sciences, University of Nebraska, Lincoln, NE 68583-0907, USADepartment of Animal Science, University of Nebraska, Lincoln, NE 68583-0908, USAUnited States Meat Animal Research Center, Clay Center, NE 68933, USASchool of Veterinary Medicine and Biomedical Sciences, University of Nebraska, Lincoln, NE 68583-0907, USADepartment of Animal Science, University of Nebraska, Lincoln, NE 68583-0908, USADepartment of Statistics, University of Nebraska, Lincoln, NE 68583-0963, USASchool of Veterinary Medicine and Biomedical Sciences, University of Nebraska, Lincoln, NE 68583-0907, USAA randomized control trial was performed over a five-year period to assess the efficacy and antibody response induced by autogenous and commercial vaccine formulations against infectious bovine keratoconjunctivitis (IBK). Calves were randomly assigned each year to one of three arms: an autogenous vaccine treatment that included <i>Moraxella bovis</i> (<i>M. bovis</i>), <i>Moraxella bovoculi</i>, and <i>Mycoplasma bovoculi</i> antigens, a commercial <i>M. bovis</i> vaccine treatment, or a sham vaccine treatment that consisted only of adjuvant. A total of 1198 calves were enrolled in the study. Calves were administered the respective vaccines approximately 21 days apart, just prior to turnout on summer pastures. Treatment effects were analyzed for IBK incidence, retreatment incidence, 205-day adjusted weaning weights, and antibody response to the type IV pilus protein (pili) of <i>M. bovis</i> as measured by a novel indirect enzyme-linked immunosorbent screening assay (ELISA). Calves vaccinated with the autogenous formulation experienced a decreased cumulative incidence of IBK over the entire study compared to those vaccinated with the commercial and sham formulations (24.5% vs. 30.06% vs. 30.3%, respectively, <i>p</i> = 0.25), and had less IBK cases that required retreatment compared to the commercial and sham formulations (21.4% vs. 27.9% vs. 34.3%, respectively, <i>p</i> = 0.15), but these differences were not significant. The autogenous formulation induced a significantly stronger antibody response than the commercial (<i>p</i> = 0.022) and sham formulations (<i>p</i> = 0.001), but antibody levels were not significantly correlated with IBK protection (<i>p</i> = 0.37).https://www.mdpi.com/2076-393X/10/6/916bovine pinkeyevaccine<i>Moraxella bovis</i><i>Moraxella bovoculi</i><i>Mycoplasma bovoculi</i>infectious bovine keratoconjunctivitis |
| spellingShingle | Matthew M. Hille Matthew L. Spangler Michael L. Clawson Kelly D. Heath Hiep L. X. Vu Rachel E. S. Rogers John Dustin Loy A Five Year Randomized Controlled Trial to Assess the Efficacy and Antibody Responses to a Commercial and Autogenous Vaccine for the Prevention of Infectious Bovine Keratoconjunctivitis Vaccines bovine pinkeye vaccine <i>Moraxella bovis</i> <i>Moraxella bovoculi</i> <i>Mycoplasma bovoculi</i> infectious bovine keratoconjunctivitis |
| title | A Five Year Randomized Controlled Trial to Assess the Efficacy and Antibody Responses to a Commercial and Autogenous Vaccine for the Prevention of Infectious Bovine Keratoconjunctivitis |
| title_full | A Five Year Randomized Controlled Trial to Assess the Efficacy and Antibody Responses to a Commercial and Autogenous Vaccine for the Prevention of Infectious Bovine Keratoconjunctivitis |
| title_fullStr | A Five Year Randomized Controlled Trial to Assess the Efficacy and Antibody Responses to a Commercial and Autogenous Vaccine for the Prevention of Infectious Bovine Keratoconjunctivitis |
| title_full_unstemmed | A Five Year Randomized Controlled Trial to Assess the Efficacy and Antibody Responses to a Commercial and Autogenous Vaccine for the Prevention of Infectious Bovine Keratoconjunctivitis |
| title_short | A Five Year Randomized Controlled Trial to Assess the Efficacy and Antibody Responses to a Commercial and Autogenous Vaccine for the Prevention of Infectious Bovine Keratoconjunctivitis |
| title_sort | five year randomized controlled trial to assess the efficacy and antibody responses to a commercial and autogenous vaccine for the prevention of infectious bovine keratoconjunctivitis |
| topic | bovine pinkeye vaccine <i>Moraxella bovis</i> <i>Moraxella bovoculi</i> <i>Mycoplasma bovoculi</i> infectious bovine keratoconjunctivitis |
| url | https://www.mdpi.com/2076-393X/10/6/916 |
| work_keys_str_mv | AT matthewmhille afiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis AT matthewlspangler afiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis AT michaellclawson afiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis AT kellydheath afiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis AT hieplxvu afiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis AT rachelesrogers afiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis AT johndustinloy afiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis AT matthewmhille fiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis AT matthewlspangler fiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis AT michaellclawson fiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis AT kellydheath fiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis AT hieplxvu fiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis AT rachelesrogers fiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis AT johndustinloy fiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis |